Green Cross Stock - GC Biopharma signs CAR-T therapy MOU
17.06.2026 - 16:54:49 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 16:51 KST. Details in the imprint.
Green Cross (KR7006280002) is drawing attention after its biopharmaceutical arm GC Biopharma signed a strategic memorandum of understanding with AbClon to co-develop in vivo CAR-T therapies. The collaboration was announced in Korean media on 06/17/2026, according to a Seoul Economic Daily report.
All news and background on Green Cross stock
Follow the latest disclosures and market data on Green Cross and GC Biopharma, from strategy updates to pipeline milestones.
Details of the AbClon CAR-T agreement
According to Seoul Economic Daily, GC Green Cross and AbClon signed a memorandum of understanding to jointly develop next-generation in vivo CAR-T therapies, combining GC Biopharma's mRNA-lipid nanoparticle platform with AbClon's CAR-T antibody technology.
The report states that the companies plan to collaborate on research and development, non-clinical studies and potential future clinical programs, with a focus on solid tumors where traditional ex vivo CAR-T has had limited success so far.
Operational significance for Green Cross
GC Biopharma, formerly Green Cross Corp., has been expanding beyond its established vaccines and plasma derivatives into advanced therapies, including gene and cell therapy platforms highlighted in recent company presentations.
The in vivo CAR-T collaboration underscores management's strategy to leverage its manufacturing capabilities and mRNA know-how to build a broader oncology pipeline, rather than relying solely on legacy blood products and vaccines for growth.
Wednesday focus on operations and strategy
From an operational standpoint, GC Biopharma has been investing in R&D, with R&D spending representing a meaningful share of revenue in recent years, as indicated in its latest annual filings and investor materials.
The AbClon tie-up fits that pattern of partnering with specialized biotech firms to access cutting-edge modalities while spreading development risk, a common approach among mid-sized Asian biopharma groups.
How the pipeline shapes long-term positioning
For Green Cross shareholders, the key question is how successfully GC Biopharma can translate early-stage initiatives like in vivo CAR-T into clinical assets and, eventually, commercial products that diversify earnings.
While the new MOU is at a preliminary stage and does not yet include disclosed financial terms or timelines, it signals continued commitment to building an oncology franchise alongside its established vaccine portfolio.
What the company sells
GC Biopharma, the core operating unit associated with Green Cross, generates most of its revenue from vaccines and plasma derivatives, including products such as its influenza vaccines and various blood plasma-derived therapies, according to company information on its official website.
Where the stock trades today
The shares of GC Biopharma, associated with Green Cross (KR7006280002), trade on the Korea Exchange (KRX) at around KRW 100,000 as of 06/17/2026, 16:30 KST.
Key facts on Green Cross stock
- Company: Green Cross Corp.
- ISIN: KR7006280002
- WKN: 095720
- Ticker: 006280
- Venue: KRX
- Price (as of 06/17/2026, 16:30 KST): 100,000 KRW
- Market cap: 1,000,000,000,000 KRW (as of 06/17/2026)
- Sector / Industry: Health Care - Biotechnology & Pharmaceuticals
- Index membership: KOSPI
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
